{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:45:41Z","timestamp":1789505141761,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.pharep.2016.01.005","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T13:53:31Z","timestamp":1453470811000},"page":"536-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Management of side effects of mTOR inhibitors in tuberous sclerosis patients"],"prefix":"10.1007","volume":"68","author":[{"given":"Krzysztof","family":"Sadowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kotulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2016.01.005_bib0245","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"MTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharep.2016.01.005_bib0250","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0255","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2016.01.005_bib0260","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(87)90416-8","article-title":"Evidence that the gene for tuberous sclerosis is on chromosome 9","volume":"1","author":"Fryer","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2016.01.005_bib0265","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","author":"The European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.pharep.2016.01.005_bib0270","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","article-title":"Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/Akt pathway","volume":"10","author":"Manning","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharep.2016.01.005_bib0275","doi-asserted-by":"crossref","first-page":"13571","DOI":"10.1073\/pnas.202476899","article-title":"Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling","volume":"99","author":"Tee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharep.2016.01.005_bib0280","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","article-title":"Effects of rapamycin in the eker rat model of tuberous sclerosis complex","volume":"57","author":"Kenerson","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharep.2016.01.005_bib0285","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.ajkd.2006.05.018","article-title":"Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex","volume":"48","author":"Wienecke","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pharep.2016.01.005_bib0290","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0295","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2016.01.005_bib0300","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2016.01.005_bib0305","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1542\/peds.2012-3607","article-title":"Possible prevention of tuberous sclerosis complex lesions","volume":"132","author":"Kotulska","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharep.2016.01.005_bib0310","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"V\u00e9zina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.pharep.2016.01.005_bib0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-5173(00)00617-7","article-title":"Solubilization of rapamycin","volume":"213","author":"Simamora","year":"2001","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharep.2016.01.005_bib0320","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical pharmacokinetics of sirolimus","volume":"40","author":"Mahalati","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharep.2016.01.005_bib0325","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharep.2016.01.005_bib0335","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejpn.2012.12.008","article-title":"Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"17","author":"J\u00f3\u017awiak","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0340","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.pediatrneurol.2015.01.004","article-title":"Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex","volume":"52","author":"Goyer","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0345","doi-asserted-by":"crossref","first-page":"e1199","DOI":"10.1542\/peds.2013-3293","article-title":"Rapid regression of left ventricular outflow tract rhabdomyoma after sirolimus therapy","volume":"134","author":"Breathnach","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.pharep.2016.01.005_bib0350","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0355","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"September","key":"10.1016\/j.pharep.2016.01.005_bib0360","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","author":"Franz","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0365","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","article-title":"Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening","volume":"26","author":"Treli\u0144ska","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.pharep.2016.01.005_bib0370","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1600-6143.2006.01678.x","article-title":"Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus","volume":"7","author":"Chuang","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.pharep.2016.01.005_bib0375","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/JNN.0b013e3182986146","article-title":"Nursing implications for the lifelong management of tuberous sclerosis complex","volume":"45","author":"Agricola","year":"2013","journal-title":"J Neurosci Nurs"},{"key":"10.1016\/j.pharep.2016.01.005_bib0380","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2217\/fon.13.141","article-title":"Mammalian target of rapamycin inhibitor-associated stomatitis","volume":"9","author":"Boers-Doets","year":"2013","journal-title":"Future Oncol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0385","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0390","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00007890-200109150-00008","article-title":"Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients","volume":"72","author":"Morelon","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.pharep.2016.01.005_bib0395","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.TP.0000118413.92211.B6","article-title":"Sirolimus-associated pulmonary toxicity","volume":"77","author":"Pham","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.pharep.2016.01.005_bib0400","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000329902","article-title":"Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors","volume":"223","author":"De Masson","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.pharep.2016.01.005_bib0405","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0026-0495(98)90239-6","article-title":"Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways","volume":"47","author":"Kraemer","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.pharep.2016.01.005_bib0410","doi-asserted-by":"crossref","first-page":"38052","DOI":"10.1074\/jbc.M106703200","article-title":"Amino acids and insulin signaling via the mTOR\/p70 S6 kinase pathway","volume":"4141","author":"Tremblay","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharep.2016.01.005_bib0415","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","article-title":"Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management","volume":"69","author":"Hong","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.pharep.2016.01.005_bib0420","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.pharep.2016.01.005_bib0425","doi-asserted-by":"crossref","first-page":"25572","DOI":"10.1074\/jbc.M002218200","article-title":"Stem cell factor\/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase\/p70 S6 kinase pathway in spermatogonia","volume":"275","author":"Feng","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharep.2016.01.005_bib0430","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.tem.2010.05.003","article-title":"Energy balance and puberty onset: emerging role of central mTOR signaling","volume":"21","author":"Roa","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharep.2016.01.005_bib0435","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.27498","article-title":"Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis","volume":"62","author":"Yoshizaki","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharep.2016.01.005_bib0440","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1017\/S1047951114002261","article-title":"Everolimus treatment of a newborn with rhabdomyoma causing severe arrhythmia","volume":"25","author":"\u00d6ztun\u00e7","year":"2015","journal-title":"Cardiol Young"},{"issue":"November","key":"10.1016\/j.pharep.2016.01.005_bib0445","article-title":"Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect","author":"Mohamed","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.pharep.2016.01.005_bib0450","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/tropej\/fmu056","article-title":"Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus","volume":"61","author":"Do\u011fan","year":"2015","journal-title":"J Trop Pediatr"},{"issue":"December","key":"10.1016\/j.pharep.2016.01.005_bib0455","article-title":"Rapid resolution of cardiac rhabdomyomas following everolimus therapy","author":"Choudhry","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"December","key":"10.1016\/j.pharep.2016.01.005_bib0460","article-title":"Safety of mTOR inhibitors in adult solid organ transplantation","author":"Aguiar","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharep.2016.01.005_bib0465","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00467-013-2459-y","article-title":"Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation","volume":"28","author":"Kranz","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0470","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s11255-009-9644-8","article-title":"Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus","volume":"42","author":"Boobes","year":"2010","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.pharep.2016.01.005_bib0475","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1600-6143.2010.03266.x","article-title":"De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation","volume":"10","author":"Pape","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.pharep.2016.01.005_bib0480","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/TP.0b013e3182295bed","article-title":"Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data","volume":"92","author":"Pape","year":"2011","journal-title":"Transplantation"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:23Z","timestamp":1752611783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2016.01.005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1734114016000104"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2016.01.005","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of side effects of mTOR inhibitors in tuberous sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2016.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}